New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
04:55 EDTACRX, ACRX, BLRX, BLRX, CRIS, CRIS, NEO, NEO, PRTA, PRTA, PTCT, PTCT, LGND, LGND, GALE, GALE, IPCI, IPCIRoth Capital to hold a conference
ROTH Healthcare Corporate Access Day to be held in London, England on June 23-24.
News For ACRX;BLRX;CRIS;NEO;PRTA;PTCT;LGND;GALE;IPCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
10:02 EDTPTCTOn the Fly: Analyst Initiation Summary
Subscribe for More Information
January 22, 2015
17:57 EDTNEONeoGenomics raises Q4 EPS view to 1c-2c from 0c-1c, consensus 0c
Raises Q4 revenue view to $25M from $23.0M-$24.5M, consensus $23.59M.
16:15 EDTPTCTPTC Therapeutics initiated with an Outperform at RBC Capital
Subscribe for More Information
08:20 EDTCRISCuris price target raised to $5 from $3 at Oppenheimer
Subscribe for More Information
January 21, 2015
09:19 EDTNEONeoGenomics shares defended at Craig-Hallum
Subscribe for More Information
07:34 EDTCRISCuris to host conference call
Conference call to discuss the Curis-Aurigene transaction will be held on January 21 at 8 am. Webcast Link
06:07 EDTCRISCuris and Aurigene Discovery announce exclusive collaboration agreement
Curis and Aurigene Discovery Technologies announced that they have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets. The collaboration provides for inclusion of multiple programs, with Curis having the option to exclusively license compounds once a development candidate is nominated within each respective program. The partnership draws from each company's respective areas of expertise, with Aurigene having the responsibility for conducting all discovery and preclinical activities, including IND-enabling studies and providing Phase 1 clinical trial supply, and Curis having responsibility for all clinical development, regulatory and commercialization efforts worldwide, excluding India and Russia, for each program for which it exercises an option to obtain a license. The first two programs under the collaboration are an orally-available small molecule antagonist of programmed death ligand-1 in the immuno-oncology field and an orally-available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 in the precision oncology field. Curis expects to exercise its option to obtain exclusive licenses to both programs and file IND applications for a development candidate from each in 2015. The agreement provides that the parties will collaborate exclusively in immuno-oncology for an initial period of approximately two years, with the option for Curis to extend the broad immuno-oncology exclusivity.In addition Curis has agreed to make payments to Aurigene as follows: For the first two programs: up to $52.5 million per program, including $42.5 million per program for approval and commercial milestones, plus specified approval milestone payments for additional indications, if any; For the third and fourth programs: up to $50 million per program, including $42.5 million per program for approval and commercial milestones, plus specified approval milestone payments for additional indications, if any; and for any program thereafter: up to $140.5 million per program, including $87.5 million per program in approval and commercial milestones, plus specified approval milestone payments for additional indications, if any. Curis has agreed to pay Aurigene royalties on any net sales ranging from high single digits to 10% in territories where it successfully commercializes products and will also share in amounts that it receives from sublicensees depending upon the stage of development of the respective molecule.
January 20, 2015
07:25 EDTGALENoble Financial to hold a conference
Subscribe for More Information
January 14, 2015
18:18 EDTGALEOn The Fly: After Hours Movers
Subscribe for More Information
16:59 EDTGALEGalena, Orexo AB receive "Paragraph IV" patent certification notice from Actavis
Subscribe for More Information
11:45 EDTBLRXBioLineRx says has resolved previous dispute with Bellerophon
Subscribe for More Information
08:16 EDTBLRXBioLineRx announces completion of enrollment in BCM CE Mark registration trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use